Today: 21 May 2026
Kenvue stock countdown: Jan. 29 merger vote looms as KVUE deal spread stays jumpy
10 January 2026
2 mins read

Kenvue stock countdown: Jan. 29 merger vote looms as KVUE deal spread stays jumpy

NEW YORK, Jan 10, 2026, 08:01 (ET) — Market closed

  • Kenvue shares closed Friday 0.9% lower, finishing at $16.83
  • The OCC memo highlighted the shareholder vote set for Jan. 29 and the related option adjustment connected to the Kimberly-Clark deal
  • Traders are eyeing the deal spread, macro data, and fresh filings ahead of the vote

Kenvue Inc (KVUE) shares slipped 0.9% on Friday, ending at $16.83 after trading between $16.75 and $17.05, retracing some of Thursday’s gains. The Options Clearing Corporation highlighted a shareholder vote set for Jan. 29 on Kenvue’s proposed merger with Kimberly-Clark and detailed a planned adjustment to KVUE options once the deal closes. They warned terms might shift as new details emerge.

Markets closed over the weekend, but KVUE is once again behaving like a deal stock. The key date ahead is the Jan. 29 vote, while merger-arbitrage funds keep a close eye on the “deal spread”—the difference between Kenvue’s current share price and the value suggested by the offer.

Based on Kimberly-Clark’s Friday close at $97.92, the stock-and-cash deal values each Kenvue share at about $17.82. That puts KVUE roughly 6% under this benchmark. The gap will fluctuate with Kimberly-Clark’s share price and investor expectations around how straightforward the second-half 2026 closing will be.

Kenvue has been steadily updating filings. In a recent Form 425 — used for merger communications — the company informed employees that Kimberly-Clark will keep current salary and target bonus levels steady for at least a year post-close. It also doesn’t expect any benefit changes to kick in during 2026, assuming the deal closes in the second half of the year. The filing noted eligible employees will get March 2026 long-term incentive awards as restricted stock units, or RSUs.

In November, Kimberly-Clark struck a deal to acquire Kenvue in a cash-and-stock transaction that values the company at roughly $48.7 billion enterprise value. The bid offers $3.50 in cash plus 0.14625 Kimberly-Clark shares for each Kenvue share. Post-merger, Kenvue shareholders would own around 46% of the combined entity. Kenvue Chair Larry Merlo described the deal as delivering “significant upfront value.” The transaction is expected to close in the second half of 2026, pending regulatory and shareholder approvals. Kenvue Investors

Earnings remain in the background but could return quickly if the deal timeline extends. Kenvue, spun off from Johnson & Johnson in 2023, is set to report quarterly results soon. Analysts expect adjusted earnings of 22 cents per share, according to Barchart. Investors will watch closely for changes in pricing, marketing expenses, and margins as the merger talks continue.

Macro factors could shake up the trade since the offer includes stock. The U.S. consumer price index for December drops Jan. 13 at 8:30 a.m. ET, with the Fed’s next meeting set for Jan. 27-28. A hotter inflation number or a shift in rate expectations could rattle Kimberly-Clark—and that directly impacts how the market values Kenvue in the deal.

The numbers add up only if the deal sails through. If the vote fails, regulators get tougher, or Kimberly-Clark’s stock takes a hit, Kenvue could be forced to stand on its own again—potentially testing the patience of investors who bought in expecting a quick exit.

Traders are back Monday, eyeing if KVUE can stay above Friday’s $16.75 low and if the discount to the offer tightens. Kimberly-Clark plans to release its fourth-quarter and full-year 2025 results on Jan. 27, with the Kenvue shareholder vote following two days later.

Stock Market Today

  • Teradyne, Kulicke and Soffa, Impinj, Microchip, IPG Photonics Stocks Slide on U.S.-China Semiconductor Summit Outcome
    May 21, 2026, 2:58 AM EDT. Shares of Teradyne, Kulicke and Soffa, Impinj, Microchip Technology, and IPG Photonics dropped sharply following the U.S.-China summit, which ended without key breakthroughs on semiconductor exports. Expectations for U.S. approval of Nvidia's H200 chip shipments to China were unmet, disappointing investors. U.S. Trade Representative Jamieson Greer indicated semiconductors were not a negotiation focus, dampening near-term optimism. Despite the sell-off, IPG Photonics' stock, known for volatility, remains down significantly from its 52-week high but has gained 34.3% year-to-date. Market reactions highlight cautious sentiment amid geopolitical tensions, with analysts skeptical about swift comprehensive deals due to national security concerns.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Lloyds share price clings to £1 as investors eye inflation data and Jan 29 results
Previous Story

Lloyds share price clings to £1 as investors eye inflation data and Jan 29 results

Why Kweichow Moutai Co., Ltd. Class A stock (600519) is in focus: iMoutai restock and a fresh target cut
Next Story

Why Kweichow Moutai Co., Ltd. Class A stock (600519) is in focus: iMoutai restock and a fresh target cut

Go toTop